The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

Tibes R, Mesa RA

The renaissance of interferon therapy for the treatment of myeloid malignancies.

Kiladjian JJ, Mesa RA, Hoffman R

Future therapies for the myeloproliferative neoplasms.

Scherber R, Mesa RA

A phase-2 trial of low-dose pomalidomide in myelofibrosis.

Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A

International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.

Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA

MPN-associated myelofibrosis (MPN-MF).

Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A

Detangling fibrosis assessment in MPNs.

Mesa RA